Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Clinical trial NCT06034964 · UNKNOWN

Trial details

NCT number: NCT06034964
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: UNKNOWN
Study type: OBSERVATIONAL

Tislelizumab Chemotherapy First-line Gastric Cancer Stage IV

Start date: 2020-11-01
Primary completion: 2022-11-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.